Short-Term Non-Benzodiazepine Options for Anxiety or Insomnia
For short-term management when avoiding benzodiazepines, prescribe either low-dose doxepin (3-6 mg) for insomnia or a non-benzodiazepine benzodiazepine receptor agonist (Z-drug) such as zolpidem, eszopiclone, or zaleplon.
Primary Medication Options
The 2019 VA/DoD guidelines specifically recommend two medication classes when behavioral therapy is unavailable or declined 1:
Low-Dose Doxepin (3-6 mg)
- Most appropriate for sleep maintenance issues (difficulty staying asleep)
- Improves sleep latency, total sleep time, and sleep quality
- No black box warning for suicide risk (unlike higher antidepressant doses)
- Adverse events comparable to placebo in clinical trials
- Effects sustained at 4 weeks 1
Non-Benzodiazepine BZRAs (Z-drugs)
Zolpidem (5 mg elderly, 10 mg non-elderly): Best for sleep onset difficulty
- Immediate-release reduces sleep latency in 45-60 minutes
- Half-life of 2.4 hours minimizes morning hangover 2
Eszopiclone or Zaleplon: Alternative options with similar efficacy
Improve sleep efficiency, sleep onset latency, sleep quality, total sleep time, and wake after sleep onset compared to placebo 1
Critical Safety Warning
The FDA issued a safety announcement regarding Z-drugs and serious injuries from complex sleep behaviors (sleepwalking, sleep driving, engaging in activities while not fully awake) 1. Screen patients for:
- History of parasomnia or sleepwalking
- Alcohol use
- Other CNS depressants
- Respiratory disorders (though Z-drugs cause minimal respiratory depression compared to benzodiazepines) 3
Clinical Decision Algorithm
If primary complaint is:
- Difficulty falling asleep → Zolpidem IR or zaleplon
- Difficulty staying asleep → Low-dose doxepin (3-6 mg) or zolpidem ER
- Middle-of-night awakening → Sublingual low-dose zolpidem (5 mg) 2
If anxiety is the primary concern rather than insomnia:
- Consider that the evidence provided focuses on insomnia management
- Z-drugs and low-dose doxepin are NOT indicated for anxiety disorders
- For anxiety without insomnia, you would need alternative non-benzodiazepine anxiolytics (buspirone, SSRIs, SNRIs) which are outside the scope of these insomnia-focused guidelines
Important Caveats
- "Short-term" means exactly that – these medications should not become chronic therapy 1, 4
- Set clear expectations upfront about duration and goals
- The evidence shows CBT-I is superior to pharmacotherapy for long-term outcomes, though equivalent at 2-4 weeks 1
- Tolerance and dependence potential is lower with Z-drugs than benzodiazepines, but still exists 3
- Rebound insomnia and withdrawal symptoms occur less frequently with Z-drugs than benzodiazepines 3
Dosing Specifics
Low-dose doxepin:
- Start 3 mg in elderly or 6 mg in younger adults
- Take 30 minutes before bedtime
Zolpidem:
- 5 mg for elderly or women, 10 mg for non-elderly men
- Take immediately before bed with at least 7-8 hours available for sleep
The evidence consistently supports these non-benzodiazepine options as first-line pharmacotherapy when medication is necessary 1, 4, 5, 6, with superior safety profiles compared to traditional benzodiazepines.